# A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

Source: https://onco.cc/trials/nct07602855/  
OnCo record `nct07602855` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ivonescimab in lung cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) is a phase 1/2, interventional study registered as NCT07602855 by GlaxoSmithKline, with a registry enrolment figure of 184 participants, started 2026-09-09 and due to reach its primary completion in 2029-06-22. Interventions recorded: Risvutatug rezetecan; Ivonescimab. Conditions listed: Neoplasms, Lung. Primary outcome: Phase 1 and Phase 2 Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs); Phase 1 and Phase 2: Number of participants with AEs leading to dose modifications including study intervention discontinuation; Phase 2: Number of part. Lung eligibility wording from the registry: "ES-SCLC". Sites: Japan, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07602855
- Phase: 1/2
- Setting: A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors
- Sponsor: GlaxoSmithKline
- Enrolled: 184

## Sources

- ClinicalTrials.gov NCT07602855: https://clinicaltrials.gov/study/NCT07602855

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07602855.json